Low-Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report

Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.

(2017) M. S. Cairo et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★

(2011) R. Reshef et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Improved Survival with Recent Post-Transplant Lymphoproliferative Disorder (PTLD) in Children with Kidney Transplants

(2011) V. R. Dharnidharka et al.   AMERICAN JOURNAL OF TRANSPLANTATION

CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation

(2011) Manuela A. Orjuela et al.   BRITISH JOURNAL OF HAEMATOLOGY

Post-transplant Burkitt lymphoma is a more aggressive and distinct form of post-transplant lymphoproliferative disorder

(2011) Jennifer Picarsic et al.   CANCER

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

(2011) Ralf Trappe et al.   LANCET ONCOLOGY

Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab/low-dose chemotherapy combination

(2010) Sushil Gupta et al.   PEDIATRIC TRANSPLANTATION

Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

(2009) Kevin Windebank et al.   PEDIATRIC BLOOD & CANCER